Weber Constance

Clinical outcomes of the PAUL® glaucoma implant: One-year results.

PGI surgery is an effective procedure for reducing IOP and pressure-lowering therapy. An intraluminal prolene stent impedes hypotony in the early postoperative phase and enables further IOP lowering without additional interventions during the postoperative course.

Two-Year Clinical Outcomes of the PAUL Glaucoma Implant in White Patients With Refractory Glaucoma.

PGI surgery is an effective procedure for reducing IOP and pressure-lowering therapy.

Influence of a Prostaglandin F2α Analogue on Corneal Hysteresis and Expression of Extracellular Matrix Metalloproteinases 3 and 9.

PGAs alter biomechanical structures by directly upregulating MMP-3 and -9, and the increase in CH is dependent on the level of IOP. Therefore, PGAs may have a greater effect when baseline IOP is higher.

Five-Year Clinical Outcomes of Inferior Quadrant Trabectome Surgery for Open Angle Glaucoma.

Trabectome surgery is a safe and relatively effective procedure for lowering IOP, but most patients still need IOP-lowering agents, and a considerable proportion may need additional glaucoma surgery within a relatively short time.

Sonographic bleb visualisation after PAUL glaucoma implant surgery.

Sonography is a suitable modality to evaluate bleb characteristics after PGI implantation.

Anterior segment OCT for imaging PAULglaucoma implant patch grafts: a useful method for follow-up and risk management.

Pericardial patch grafts tend to thin over time which can be assessed by AS-OCT, the latter proving to be a useful method to follow-up patients who undergo patch graft implantation during PGI surgery.

Clinical Outcomes of Intraluminal Stent Removal After PAUL Glaucoma Implant Surgery.

Removal of the prolene stent following PGI surgery effectively lowers IOP in the short term, with a moderate increase in IOP and need for pressure-lowering therapy over time.

Ocular drug delivery systems: glaucoma patient perceptions from a German university hospital eye clinic.

ODD for the treatment of glaucoma were broadly deemed acceptable by patients in this study.